Mollstedt J, Mansouri L, Rosenquist R. Precision diagnostics in chronic lymphocytic leukemia: past, present and future. Front Oncol. 2023;13:1146486.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shadman M. Diagnosis and treatment of chronic lymphocytic leukemia: a review. JAMA. 2023;329(11):918–32.

Article  CAS  PubMed  Google Scholar 

Karr M, Roeker L. A history of targeted therapy development and progress in novel–novel combinations for chronic lymphocytic leukemia (CLL). Cancers. 2023;15(4):1018.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Asgarian-Omran H, Forghani P, Hojjat-Farsangi M, Roohi A, Sharifian RA, Razavi SM, et al. Expression profile of galectin-1 and galectin-3 molecules in different subtypes of chronic lymphocytic leukemia. Cancer Invest. 2010;28(7):717–25.

Article  CAS  PubMed  Google Scholar 

Sun C, Chen Y-C, Martinez Zurita A, Baptista MJ, Pittaluga S, Liu D, et al. The immune microenvironment shapes transcriptional and genetic heterogeneity in chronic lymphocytic leukemia. Blood Adv. 2023;7(1):145–58.

Article  CAS  PubMed  Google Scholar 

Palma M, Gentilcore G, Heimersson K, Mozaffari F, Näsman-Glaser B, Young E, et al. T cells in chronic lymphocytic leukemia display dysregulated expression of immune checkpoints and activation markers. Haematologica. 2017;102(3):562.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Roessner PM, Seiffert M. T-cells in chronic lymphocytic leukemia: guardians or drivers of disease? Leukemia. 2020;34(8):2012–24.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cutucache CE. Tumor-induced host immunosuppression: special focus on CLL. Int Immunopharmacol. 2013;17(1):35–41.

Article  CAS  PubMed  Google Scholar 

Ding W, LaPlant BR, Call TG, Parikh SA, Leis JF, He R, et al. Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL. Blood, J Am Soc Hematol. 2017;129(26):3419–27.

CAS  Google Scholar 

Ntsethe A, Dludla PV, Nyambuya TM, Ngcobo SR, Nkambule BB. The impact of immune checkpoint inhibitors in patients with chronic lymphocytic leukemia (CLL): a protocol for a systematic review and meta-analysis of randomized controlled trials. Medicine. 2020;99(28):e21167. https://doi.org/10.1097/MD.0000000000021167.

Arruga F, Gyau BB, Iannello A, Vitale N, Vaisitti T, Deaglio S. Immune response dysfunction in chronic lymphocytic leukemia: dissecting molecular mechanisms and microenvironmental conditions. Int J Mol Sci. 2020;21(5):1825.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nirschl CJ, Drake CG. Molecular pathways: coexpression of immune checkpoint molecules: signaling pathways and implications for cancer immunotherapy. Clin Cancer Res. 2013;19(18):4917–24.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Weber R, Fleming V, Hu X, Nagibin V, Groth C, Altevogt P, Utikal J, Umansky V. Myeloid-Derived Suppressor Cells Hinder the Anti-Cancer Activity of Immune Checkpoint Inhibitors. Front Immunol. 2018;9:1310. https://doi.org/10.3389/fimmu.2018.01310.

Nicholas NS, Apollonio B, Ramsay AG. Tumor microenvironment (TME)-driven immune suppression in B cell malignancy. Biochimica et Biophysica Acta -Molecular Cell Research. 2016;1863(3):471–82.

Article  CAS  Google Scholar 

Pianko MJ, Liu Y, Bagchi S, Lesokhin AM. Immune checkpoint blockade for hematologic malignancies: a review. Stem Cell Investig. 2017;4:32. https://doi.org/10.21037/sci.2017.03.04.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Peranzoni E, Ingangi V, Masetto E, Pinton L, Marigo I. Myeloid Cells as Clinical Biomarkers for Immune Checkpoint Blockade. Front Immunol. 2020;11:1590. https://doi.org/10.3389/fimmu.2020.01590.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Twomey JD, Zhang B. Cancer immunotherapy update: FDA-approved checkpoint inhibitors and companion diagnostics. AAPS J. 2021;23(2):1–11.

Article  Google Scholar 

Zhang H, Houghton AM. Therapeutics Good cops turn bad: the contribution of neutrophils to immune-checkpoint inhibitor treatment failures in cancer. Pharmacology. 2021;217:107662.

CAS  Google Scholar 

Zaretsky JM, Garcia-Diaz A, Shin DS, Escuin-Ordinas H, Hugo W, Hu-Lieskovan S, et al. Mutations associated with acquired resistance to PD-1 blockade in melanoma. N Engl J Med. 2016;375(9):819–29.

Article  CAS  PubMed  PubMed Central  Google Scholar 

O’Donnell JS, Long GV, Scolyer RA, Teng MW, Smyth MJ. Resistance to PD1/PDL1 checkpoint inhibition. Cancer Treat Rev. 2017;52:71–81.

Article  PubMed  Google Scholar 

Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma. N Engl J Med. 2015;372(4):311–9.

Article  PubMed  Google Scholar 

Svanberg R, Janum S, Patten PE, Ramsay AG, Niemann CU. Targeting the tumor microenvironment in chronic lymphocytic leukemia. Haematologica. 2021;106(9):2312.

Article  PubMed  PubMed Central  Google Scholar 

Ramsay AG, Clear AJ, Fatah R, Gribben JG. Multiple inhibitory ligands induce impaired T-cell immunologic synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide: establishing a reversible immune evasion mechanism in human cancer. Blood, J Ame Soc Hematol. 2012;120(7):1412–21.

CAS  Google Scholar 

Riches JC, Davies JK, McClanahan F, Fatah R, Iqbal S, Agrawal S, et al. T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production. Blood, J Am Soc Hematol. 2013;121(9):1612–21.

CAS  Google Scholar 

McClanahan F, Hanna B, Miller S, Clear AJ, Lichter P, Gribben JG, et al. PD-L1 checkpoint blockade prevents immune dysfunction and leukemia development in a mouse model of chronic lymphocytic leukemia. Blood, J Am Soc Hematol. 2015;126(2):203–11.

CAS  Google Scholar 

Khan M, Arooj S, Wang H. NK cell-based immune checkpoint inhibition. Front Immunol. 2020;11:167.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rudd CE, Taylor A, Schneider H. CD28 and CTLA-4 coreceptor expression and signal transduction. Immunol Rev. 2009;229(1):12–26.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Atanackovic D, Luetkens T. Biomarkers for checkpoint inhibition in hematologic malignancies. Semin Cancer Biol. 2018;52(Pt 2):198–206. https://doi.org/10.1016/j.semcancer.2018.05.005.

Article  CAS  PubMed  Google Scholar 

Peggs KS, Quezada SA, Chambers CA, Korman AJ, Allison JP. Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti–CTLA-4 antibodies. J Exp Med. 2009;206(8):1717–25.

Article  CAS  PubMed  PubMed Central  Google Scholar 

clinicaltrials.gov [Available from: https://clinicaltrials.gov/.

Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711–23.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Comin-Anduix B, Escuin-Ordinas H, Ibarrondo FJ. Tremelimumab: research and clinical development. Onco Targets Ther. 2016;9:1767.

CAS  PubMed  PubMed Central  Google Scholar 

Frydecka I, Kosmaczewska A, Bocko D, Ciszak L, Wolowiec D, Kuliczkowski K, et al. Alterations of the expression of T-cell-related costimulatory CD28 and downregulatory CD152 (CTLA-4) molecules in patients with B-cell chronic lymphocytic leukaemia. Br J Cancer. 2004;90(10):2042–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Motta M, Rassenti L, Shelvin B, Lerner S, Kipps T, Keating M, et al. Increased expression of CD152 (CTLA-4) by normal T lymphocytes in untreated patients with B-cell chronic lymphocytic leukemia. Leukemia. 2005;19(10):1788–93.

Article  CAS  PubMed  Google Scholar 

Kosmaczewska A, Ciszak L, Suwalska K, Wolowiec D, Frydecka I. CTLA-4 overexpression in CD19+/CD5+ cells correlates with the level of cell cycle regulators and disease progression in B-CLL patients. Leukemia. 2005;19(2):301–4.

Article  CAS  PubMed  Google Scholar 

Ciszak L, Frydecka I, Wolowiec D, Szteblich A, Kosmaczewska A. Patients with chronic lymphocytic leukaemia (CLL) differ in the pattern of CTLA-4 expression on CLL cells: the possible implications for immunotherapy with CTLA-4 blocking antibody. Tumor Biol. 2016;37(3):4143–57.

Article  CAS  Google Scholar 

Joshi AD, Hegde GV, Dickinson JD, Mittal AK, Lynch JC, Eudy JD, et al. ATM, CTLA4, MNDA, and HEM1 in high versus low CD38–expressing B-cell chronic lymphocytic leukemia. Clin Cancer Res. 2007;13(18):5295–304.

Article  CAS  PubMed  Google Scholar 

Mittal AK, Chaturvedi NK, Rohlfsen RA, Gupta P, Joshi AD, Hegde GV, et al. Role of CTLA4 in the proliferation and survival of chronic lymphocytic leukemia. PLoS ONE. 2013;8(8):e70352.

Article  CAS  PubMed  PubMed Central